vs
安霸（AMBA）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是安霸的1.8倍（$199.9M vs $108.5M），安霸净利率更高（-13.9% vs -29.5%，领先15.6%），安霸同比增速更快（31.2% vs -5.9%），安霸自由现金流更多（$31.4M vs $-14.3M），过去两年安霸的营收复合增速更高（45.0% vs 7.7%）
安霸是美国无晶圆厂半导体设计企业，专注于低功耗高清、超高清视频压缩、图像处理及计算机视觉处理器研发。其芯片产品广泛应用于视频安防、高级驾驶辅助系统、电子后视镜、行车记录仪、驾驶舱内监测、自动驾驶、机器人等多元人机视觉场景。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AMBA vs APLS — 直观对比
营收规模更大
APLS
是对方的1.8倍
$108.5M
营收增速更快
AMBA
高出37.1%
-5.9%
净利率更高
AMBA
高出15.6%
-29.5%
自由现金流更多
AMBA
多$45.7M
$-14.3M
两年增速更快
AMBA
近两年复合增速
7.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.5M | $199.9M |
| 净利润 | $-15.1M | $-59.0M |
| 毛利率 | 59.6% | — |
| 营业利润率 | -15.0% | -25.6% |
| 净利率 | -13.9% | -29.5% |
| 营收同比 | 31.2% | -5.9% |
| 净利润同比 | 37.2% | -62.2% |
| 每股收益（稀释后） | $-0.35 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMBAAPLS
| Q4 25 | $108.5M | $199.9M | ||
| Q3 25 | $95.5M | $458.6M | ||
| Q2 25 | $85.9M | $178.5M | ||
| Q1 25 | $84.0M | $166.8M | ||
| Q4 24 | $82.7M | $212.5M | ||
| Q3 24 | $63.7M | $196.8M | ||
| Q2 24 | $54.5M | $199.7M | ||
| Q1 24 | $51.6M | $172.3M |
净利润AMBAAPLS
| Q4 25 | $-15.1M | $-59.0M | ||
| Q3 25 | $-20.0M | $215.7M | ||
| Q2 25 | $-24.3M | $-42.2M | ||
| Q1 25 | $-20.2M | $-92.2M | ||
| Q4 24 | $-24.1M | $-36.4M | ||
| Q3 24 | $-34.9M | $-57.4M | ||
| Q2 24 | $-37.9M | $-37.7M | ||
| Q1 24 | $-60.6M | $-66.4M |
毛利率AMBAAPLS
| Q4 25 | 59.6% | — | ||
| Q3 25 | 58.9% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 60.0% | — | ||
| Q4 24 | 60.6% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 59.8% | — |
营业利润率AMBAAPLS
| Q4 25 | -15.0% | -25.6% | ||
| Q3 25 | -23.0% | 48.7% | ||
| Q2 25 | -30.1% | -18.6% | ||
| Q1 25 | -30.2% | -50.0% | ||
| Q4 24 | -30.9% | -12.3% | ||
| Q3 24 | -56.9% | -24.0% | ||
| Q2 24 | -72.4% | -14.7% | ||
| Q1 24 | -80.8% | -36.0% |
净利率AMBAAPLS
| Q4 25 | -13.9% | -29.5% | ||
| Q3 25 | -20.9% | 47.0% | ||
| Q2 25 | -28.3% | -23.6% | ||
| Q1 25 | -24.1% | -55.3% | ||
| Q4 24 | -29.1% | -17.1% | ||
| Q3 24 | -54.8% | -29.2% | ||
| Q2 24 | -69.6% | -18.9% | ||
| Q1 24 | -117.4% | -38.5% |
每股收益（稀释后）AMBAAPLS
| Q4 25 | $-0.35 | $-0.40 | ||
| Q3 25 | $-0.47 | $1.67 | ||
| Q2 25 | $-0.58 | $-0.33 | ||
| Q1 25 | $-0.48 | $-0.74 | ||
| Q4 24 | $-0.58 | $-0.30 | ||
| Q3 24 | $-0.85 | $-0.46 | ||
| Q2 24 | $-0.93 | $-0.30 | ||
| Q1 24 | $-1.51 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.1M | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $590.1M | $370.1M |
| 总资产 | $751.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMBAAPLS
| Q4 25 | $174.1M | $466.2M | ||
| Q3 25 | $142.7M | $479.2M | ||
| Q2 25 | $141.3M | $370.0M | ||
| Q1 25 | $144.6M | $358.4M | ||
| Q4 24 | $127.1M | $411.3M | ||
| Q3 24 | $153.9M | $396.9M | ||
| Q2 24 | $131.8M | $360.1M | ||
| Q1 24 | $144.9M | $325.9M |
总债务AMBAAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益AMBAAPLS
| Q4 25 | $590.1M | $370.1M | ||
| Q3 25 | $576.5M | $401.2M | ||
| Q2 25 | $572.7M | $156.3M | ||
| Q1 25 | $561.4M | $164.2M | ||
| Q4 24 | $554.3M | $228.5M | ||
| Q3 24 | $547.6M | $237.1M | ||
| Q2 24 | $555.4M | $264.3M | ||
| Q1 24 | $559.9M | $266.7M |
总资产AMBAAPLS
| Q4 25 | $751.9M | $1.1B | ||
| Q3 25 | $706.4M | $1.1B | ||
| Q2 25 | $701.9M | $821.4M | ||
| Q1 25 | $689.0M | $807.3M | ||
| Q4 24 | $670.8M | $885.1M | ||
| Q3 24 | $650.3M | $901.9M | ||
| Q2 24 | $638.7M | $904.5M | ||
| Q1 24 | $657.7M | $831.9M |
负债/权益比AMBAAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.3M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $31.4M | $-14.3M |
| 自由现金流率自由现金流/营收 | 29.0% | -7.1% |
| 资本支出强度资本支出/营收 | 2.7% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $64.3M | $45.0M |
8季度趋势，按日历期对齐
经营现金流AMBAAPLS
| Q4 25 | $34.3M | $-14.2M | ||
| Q3 25 | $5.5M | $108.5M | ||
| Q2 25 | $14.8M | $4.4M | ||
| Q1 25 | $25.4M | $-53.4M | ||
| Q4 24 | $6.6M | $19.4M | ||
| Q3 24 | $16.7M | $34.1M | ||
| Q2 24 | $-15.0M | $-8.3M | ||
| Q1 24 | $-4.0M | $-133.0M |
自由现金流AMBAAPLS
| Q4 25 | $31.4M | $-14.3M | ||
| Q3 25 | $1.4M | $108.3M | ||
| Q2 25 | $10.2M | $4.4M | ||
| Q1 25 | $21.2M | $-53.4M | ||
| Q4 24 | $4.1M | $19.3M | ||
| Q3 24 | $14.2M | — | ||
| Q2 24 | $-16.1M | $-8.4M | ||
| Q1 24 | $-6.0M | $-133.3M |
自由现金流率AMBAAPLS
| Q4 25 | 29.0% | -7.1% | ||
| Q3 25 | 1.4% | 23.6% | ||
| Q2 25 | 11.9% | 2.5% | ||
| Q1 25 | 25.3% | -32.0% | ||
| Q4 24 | 5.0% | 9.1% | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -29.5% | -4.2% | ||
| Q1 24 | -11.6% | -77.3% |
资本支出强度AMBAAPLS
| Q4 25 | 2.7% | 0.1% | ||
| Q3 25 | 4.3% | 0.0% | ||
| Q2 25 | 5.3% | 0.0% | ||
| Q1 25 | 5.0% | 0.0% | ||
| Q4 24 | 3.0% | 0.0% | ||
| Q3 24 | 4.0% | 0.0% | ||
| Q2 24 | 2.1% | 0.0% | ||
| Q1 24 | 3.7% | 0.2% |
现金转化率AMBAAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
